Data from Landmark Michael J. Fox Foundation Study Shows Impact of Promising Parkinson’s Therapy

Promising New Therapy for Slowing Parkinson’s Disease Breakthrough Trial Results: In October 2024, Roche (pharma giant) shared encouraging results for a new Parkinson's disease therapy, prasinezumab, which may help slow down the disease’s progression. Using data from The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative, researchers found that patients treated with prasinezumab experienced disease progression at least 40% slower than usual. Patients who received the treatment for a longer period showed even greater benefits. How Data from the Parkinson’s Progression Markers Initiative Makes This Possible: The Parkinson’s Progression Markers Initiative study, started in 2010, has collected valuable information from thousands of Parkinson's patients worldwide to help researchers understand how the disease progresses. For this trial, data from the Parkinson’s Progression Markers Initiative served as a baseline to compare how quickly the disease would typically progress, allowing Roche to see the positive impact of prasinezumab more clearly. Sohini Chowdhury from the Michael J. Fox Foundation noted that data contributions from this study demonstrate the valuable role of volunteers in advancing Parkinson’s research. Early Findings and Follow-Up Study: Prasinezumab targets a specific protein in the brain called alpha-synuclein that may play a role in slowing cell damage in Parkinson’s. While the first study didn’t show big changes across all measures, patients on prasinezumab did show slower progression in specific motor symptoms. In a follow-up study, all participants received prasinezumab, and researchers used data from the Parkinson’s Progression Markers Initiative to understand how well the drug worked over time. Future Prospects: Roche has launched a new study, the PADOVA trial, involving over 500 participants, to further explore the benefits of prasinezumab in slowing Parkinson’s disease. Participant Marty Acevedo, who joined the Parkinson’s Progression Markers Initiative to contribute to a future cure, shared, “I’m proud that my contributions have led to promise for this and other treatments and am hopeful for a day when we end Parkinson’s.”